Cargando…

Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) impacted healthcare, the workforce, and worldwide socioeconomics. Multi-dose mono- or bivalent mRNA vaccine regimens have shown high efficacy in protection against SARS-CoV-2 and its emerging variants wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yalcin, Dicle, Bennett, Sydney J., Sheehan, Jared, Trauth, Amber J., Tso, For Yue, West, John T., Hagensee, Michael E., Ramsay, Alistair J., Wood, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138620/
https://www.ncbi.nlm.nih.gov/pubmed/37108460
http://dx.doi.org/10.3390/ijms24087292
_version_ 1785032750286241792
author Yalcin, Dicle
Bennett, Sydney J.
Sheehan, Jared
Trauth, Amber J.
Tso, For Yue
West, John T.
Hagensee, Michael E.
Ramsay, Alistair J.
Wood, Charles
author_facet Yalcin, Dicle
Bennett, Sydney J.
Sheehan, Jared
Trauth, Amber J.
Tso, For Yue
West, John T.
Hagensee, Michael E.
Ramsay, Alistair J.
Wood, Charles
author_sort Yalcin, Dicle
collection PubMed
description The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) impacted healthcare, the workforce, and worldwide socioeconomics. Multi-dose mono- or bivalent mRNA vaccine regimens have shown high efficacy in protection against SARS-CoV-2 and its emerging variants with varying degrees of efficacy. Amino acid changes, primarily in the receptor-binding domain (RBD), result in selection for viral infectivity, disease severity, and immune evasion. Therefore, many studies have centered around neutralizing antibodies that target the RBD and their generation achieved through infection or vaccination. Here, we conducted a unique longitudinal study, analyzing the effects of a three-dose mRNA vaccine regimen exclusively using the monovalent BNT162b2 (Pfizer/BioNTech) vaccine, systematically administered to nine previously uninfected (naïve) individuals. We compare changes in humoral antibody responses across the entire SARS-CoV-2 spike glycoprotein (S) using a high-throughput phage display technique (VirScan). Our data demonstrate that two doses of vaccination alone can achieve the broadest and highest magnitudes of anti-S response. Moreover, we present evidence of novel highly boosted non-RBD epitopes that strongly correlate with neutralization and recapitulate independent findings. These vaccine-boosted epitopes could facilitate multi-valent vaccine development and drug discovery.
format Online
Article
Text
id pubmed-10138620
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101386202023-04-28 Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations Yalcin, Dicle Bennett, Sydney J. Sheehan, Jared Trauth, Amber J. Tso, For Yue West, John T. Hagensee, Michael E. Ramsay, Alistair J. Wood, Charles Int J Mol Sci Article The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) impacted healthcare, the workforce, and worldwide socioeconomics. Multi-dose mono- or bivalent mRNA vaccine regimens have shown high efficacy in protection against SARS-CoV-2 and its emerging variants with varying degrees of efficacy. Amino acid changes, primarily in the receptor-binding domain (RBD), result in selection for viral infectivity, disease severity, and immune evasion. Therefore, many studies have centered around neutralizing antibodies that target the RBD and their generation achieved through infection or vaccination. Here, we conducted a unique longitudinal study, analyzing the effects of a three-dose mRNA vaccine regimen exclusively using the monovalent BNT162b2 (Pfizer/BioNTech) vaccine, systematically administered to nine previously uninfected (naïve) individuals. We compare changes in humoral antibody responses across the entire SARS-CoV-2 spike glycoprotein (S) using a high-throughput phage display technique (VirScan). Our data demonstrate that two doses of vaccination alone can achieve the broadest and highest magnitudes of anti-S response. Moreover, we present evidence of novel highly boosted non-RBD epitopes that strongly correlate with neutralization and recapitulate independent findings. These vaccine-boosted epitopes could facilitate multi-valent vaccine development and drug discovery. MDPI 2023-04-14 /pmc/articles/PMC10138620/ /pubmed/37108460 http://dx.doi.org/10.3390/ijms24087292 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yalcin, Dicle
Bennett, Sydney J.
Sheehan, Jared
Trauth, Amber J.
Tso, For Yue
West, John T.
Hagensee, Michael E.
Ramsay, Alistair J.
Wood, Charles
Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations
title Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations
title_full Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations
title_fullStr Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations
title_full_unstemmed Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations
title_short Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations
title_sort longitudinal variations in antibody responses against sars-cov-2 spike epitopes upon serial vaccinations
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10138620/
https://www.ncbi.nlm.nih.gov/pubmed/37108460
http://dx.doi.org/10.3390/ijms24087292
work_keys_str_mv AT yalcindicle longitudinalvariationsinantibodyresponsesagainstsarscov2spikeepitopesuponserialvaccinations
AT bennettsydneyj longitudinalvariationsinantibodyresponsesagainstsarscov2spikeepitopesuponserialvaccinations
AT sheehanjared longitudinalvariationsinantibodyresponsesagainstsarscov2spikeepitopesuponserialvaccinations
AT trauthamberj longitudinalvariationsinantibodyresponsesagainstsarscov2spikeepitopesuponserialvaccinations
AT tsoforyue longitudinalvariationsinantibodyresponsesagainstsarscov2spikeepitopesuponserialvaccinations
AT westjohnt longitudinalvariationsinantibodyresponsesagainstsarscov2spikeepitopesuponserialvaccinations
AT hagenseemichaele longitudinalvariationsinantibodyresponsesagainstsarscov2spikeepitopesuponserialvaccinations
AT ramsayalistairj longitudinalvariationsinantibodyresponsesagainstsarscov2spikeepitopesuponserialvaccinations
AT woodcharles longitudinalvariationsinantibodyresponsesagainstsarscov2spikeepitopesuponserialvaccinations